Biotechnology

Canyon Labs Announces New Leadership Hires

March 13, 2024 9:00 AM

Canyon Labs Hires Sales and Technical Business Development Leadership SALT LAKE CITY, UT / ACCESSWIRE / March 13, 2024 / Canyon Labs, a leader in testing and regulatory consulting for medical devices and pharmaceuticals, announces today the hire of new company leadership. These new hires will bring industry expertise to continue to elevate the offerings and business solutions to current and future customers. Kyle Kempf, Vice President of Sales...

Read more

Chief Financial Officer (CFO) Ole Larsen Buys Shares

March 13, 2024 6:35 AM

KØBENHAVN, DK / ACCESSWIRE / March 13, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - 13 March 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today announces that Ole Larsen (CFO) has bought shares. Member of the Executive Management Ole Larsen has bought 529 shares in the Company at an average share price of SEK 54.364. After the buy, Ole holds 3,000 shares in the Company. For further information, please contact: Morten Albrechtsen,...

Read more

Moolec Science Presents Second Quarter Fiscal Year 2024 Business Update

March 13, 2024 6:30 AM

LUXEMBOURG / ACCESSWIRE / March 13, 2024 / Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the second quarter of Fiscal Year 2024 ended December 31, 2023. Moolec Logo Moolec Science Logo The main highlights of Moolec's business update are as follows: SOOY1 | Piggy Sooy™ Platform: Third generation...

Read more

AbTherx Partners with Single Cell Technology for First Antibody Discovery Campaigns

March 13, 2024 6:00 AM

Partnership provides AbTherx and licensees of AbTherx's Atlas™ Mice access to Single Cell Technology's proprietary single B cell screening engine MOUNTAIN VIEW AND SAN JOSE, CA / ACCESSWIRE / March 13, 2024 / AbTherx, Inc., a biotechnology company with innovative technologies to enable and accelerate antibody discovery, and Single Cell Technology, Inc. ("Single Cell"), a biotechnology company with nine years of experience delivering antibodies...

Read more

Interventional DiviTum(R) TKa Trial Launches at Washington University

March 13, 2024 3:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / March 13, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, today announces that a clinical trial, BettER, is being launched at Washington University School of Medicine in St. Louis. The study is aimed at evaluating whether patients with HR+ HER2- metastatic or unresectable breast cancer benefit from DiviTum® TKa "We are thrilled to once again...

Read more

Bioriginal and POS Biosciences Launch Sustainable Omega-3 Line

March 12, 2024 4:10 PM

SASKATOON, SK / ACCESSWIRE / March 12, 2024 / Bioriginal Food & Science Corp. ("Bioriginal"), a wholly owned subsidiary of Cooke Inc. ("Cooke"), has developed a sustainable line of omega-3 fish, algal, and plant based oils with technology from POS Biosciences. Leveraging Cooke's marine resources as a global aquaculture fish farmer, Bioriginal has access to a secure source of sustainable fish oil. Combining these new fish oil products with an...

Read more

Elixirgen Scientific Achieves ISO 9001 QMS Certification

March 12, 2024 9:00 AM

Baltimore-based biotechnology leader, Elixirgen Scientific, Inc., achieves ISO 9001:2015 Quality Management System certification, strengthening commitment to quality, excellence in biotechnology and drug discovery. BALTIMORE, MD / ACCESSWIRE / March 12, 2024 / Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through iPSC technology, announced today that it has been accredited...

Read more

Vibrant Wellness Introduces Regenere: A Revolutionary Personalized Skincare Regimen

March 12, 2024 8:15 AM

Harnessing Genetic Insights for Better Skincare Solutions SANTA CLARA, CA / ACCESSWIRE / March 12, 2024 / Vibrant Wellness, a pioneer in personalized wellness solutions, announced the launch of Regenere - an innovative skincare regimen that redefines personalized skincare. By leveraging genetic insights and detailed skin assessments, Regenere helps address individual skincare needs. Personalized Skincare Receive your personalized skincare...

Read more

Canopus Biopharma Inc. (CBIA) dba Blue Heaven Coffee Inc. (BHC) Leads Retail Revolution with Introduction of Innovative Customer Loyalty Program

March 12, 2024 8:00 AM

LAS VEGAS, NV / ACCESSWIRE / March 12, 2024 / Canopus Biopharma Inc. (OTC PINK:CBIA) dba Blue Heaven Coffee Inc. (BHC) is at the forefront of retail innovation with the introduction of its groundbreaking customer loyalty program. Leveraging the success of its AI-powered digital vending machines, BHC has unveiled a pioneering loyalty initiative tailored exclusively for users of its unattended retail network across North America. This innovative...

Read more

Biovica Signs Master Service Agreement

March 12, 2024 3:20 AM

UPPSALA, SE / ACCESSWIRE / March 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a biopharmaceutical company enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several work orders, the first of which is 1.2 MSEK. The service agreement allows Biovica to perform TKa testing services...

Read more

Prolocor Announces Appointment of Raymond Russo as Chief Commercial Officer

March 11, 2024 8:00 AM

PHILADELPHIA, PA / ACCESSWIRE / March 11, 2024 / Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa (pFCG test), today announced the appointment of Raymond Russo as Chief Commercial Officer. Mr. Russo is a seasoned biotech executive with significant operational, commercial, and strategic leadership experience across cardiovascular and...

Read more

GenEmbryomics Prepares for US National Exchange Listing with Appointment of Independent US-Based Director

March 7, 2024 5:15 PM

MELBOURNE, AUSTRALIA / ACCESSWIRE / March 7, 2024 / GenEmbryomics, a medical genetics company with world-leading intellectual property, today announced the appointment of an additional independent director to its Board. This strategic move is part of the company's preparation for listing on a major US national exchange, underlining its commitment to global expansion and enhancing corporate governance standards. "We are thrilled to welcome Tess...

Read more

Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

March 7, 2024 4:15 PM

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024....

Read more

RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX

March 7, 2024 12:25 PM

Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 7, 2024 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB:OCEL) today reported that the Financial Industry Regulatory Agency ("FINRA") completed the processing of the Company's Corporate Action Notification Form filed with respect to...

Read more

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

March 7, 2024 9:05 AM

First-ever dissolvable DehydraTECH-GLP-1 oral dose formulation to be tested Rybelsus® semaglutide will act as the positive control KELOWNA, BC / ACCESSWIRE / March 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's second DehydraTECH-powered glucagon-like peptide 1...

Read more

Edesa Biotech to Participate in Barclays Global Healthcare Conference

March 7, 2024 8:45 AM

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management will participate in the Barclays 26th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024. Attendees interested in meeting with Edesa can request meetings...

Read more

AbTherx Appoints Janine Schuurman, PhD, as Scientific Advisor

March 7, 2024 6:00 AM

Antibody expert and co-inventor of DuoBody®, HexaBody®, and HexElect® technologies joins AbTherx to drive expansion of the Atlas™ Mice platform MOUNTAIN VIEW, CA / ACCESSWIRE / March 7, 2024 / AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Janine Schuurman, PhD, as a scientific advisor. In her new role, Dr. Schuurman will provide guidance on...

Read more

Biovica Signs Master Service Agreement for TKa Testing with Leading Pharma Company

March 7, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / March 7, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a leading tier-1 pharmaceutical company, enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several expected work orders, the first of which is 1.7 MSEK. This service agreement enables the evaluation...

Read more

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting

March 6, 2024 8:40 AM

97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS)) 74% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at Six Months (Improvement in rVCSS of 3 or More Points) Average rVCSS Improvement Per Patient is 8 Points, More Than Two and a Half Times the Amount Needed to Show the VenoValve's Clinically Meaningful Benefit Company on...

Read more

Moolec Science to Host Second Quarter Fiscal Year 2024 Business Update Conference Call

March 6, 2024 8:00 AM

LUXEMBOURG / ACCESSWIRE / March 6, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Second Quarter Fiscal Year 2024 on Wednesday, March 13, 2024, before the market opens. logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José...

Read more